This product profile provides a clinical overview of the best-in-class protease inhibitor (PI) formulated in a fixed-dose combination (FDC) of
ritonavir-boosted darunavir at a strength of DRV/r 120mg/20mg (pDRV/r). It also covers market updates and implementation considerations, and provides answers to frequently asked questions about this optimal product.